Unstable Angina Market on Track for Major Expansion by 2032, According to DelveInsight
The Key Unstable Angina Companies in the market include - Tasly Pharmaceuticals, Arbor Pharmaceuticals, and others.
The Unstable Angina market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Unstable Angina pipeline products will significantly revolutionize the Unstable Angina market dynamics.
DelveInsight's 'Unstable Angina Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Unstable Angina, historical and forecasted epidemiology as well as the Unstable Angina market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Unstable Angina market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Some of the key facts of the Unstable Angina Market Report:
The Unstable Angina market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In November 2024, Saghmos is developing ST-62516 (trimetazidine), a cardiorenal metabolic modulator aimed at lowering the risk of Acute Kidney Injury (AKI) and Major Adverse Cardiac and Kidney Events (MACKE) following contrast-based procedures like percutaneous coronary intervention (PCI). In the US, over one million PCI procedures are performed annually on patients with unstable angina, with around half having additional health conditions that affect PCI safety. This represents a significant unmet medical need, as no FDA-approved treatments currently exist to prevent or manage AKI and MACKE. Saghmos Therapeutics is partnering with the Duke Clinical Research Institute to refine and execute the Phase 3 trial for ST-62516.
Coronary heart disease (CHD) impacts over 17 million adults in the United States. Of the 17 million Americans affected, 55% of those are male. Angina affects 10 million people in the United States
According to the study of Nathan Messas, Unstable Angina or Angina pectoris is the most prevalent manifestation of myocardial ischemia and coronary artery disease (CAD), affecting up to 9 million patients in the United States
Key Unstable Angina Companies: Tasly Pharmaceuticals, Arbor Pharmaceuticals, and others
Key Unstable Angina Therapies: T89, AR36, and others
The Unstable Angina epidemiology based on gender analyzed that it can be concluded that Unstable Angina is more common in males than female
Unstable Angina Overview
Unstable angina is a type of chest pain that occurs suddenly and unpredictably due to reduced blood flow to the heart. It is a medical emergency and a warning sign of an impending heart attack. Unlike stable angina, it can occur at rest, lasts longer, and may not be relieved by medication or rest. It results from the rupture of a plaque in the coronary artery, leading to partial blockage. Immediate treatment is essential to restore blood flow and prevent heart damage.
Unstable Angina Market
The dynamics of the Unstable Angina market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
'The emerging pipeline for the treatment of Unstable Angina have few candidates. These products are in mid or last stage of investigation. With the launch of emerging therapies the total market of Unstable Angina is supposed to experience immense changes in the future'
Unstable Angina Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Unstable Angina Epidemiology Segmentation:
The Unstable Angina market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Unstable Angina Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Unstable Angina market or expected to get launched during the study period. The analysis covers Unstable Angina market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Unstable Angina Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Unstable Angina Therapies and Key Companies
Scope of the Unstable Angina Market Report
Table of Contents
1. Unstable Angina Market Report Introduction
2. Executive Summary for Unstable Angina
3. SWOT analysis of Unstable Angina
4. Unstable Angina Patient Share (%) Overview at a Glance
5. Unstable Angina Market Overview at a Glance
6. Unstable Angina Disease Background and Overview
7. Unstable Angina Epidemiology and Patient Population
8. Country-Specific Patient Population of Unstable Angina
9. Unstable Angina Current Treatment and Medical Practices
10. Unstable Angina Unmet Needs
11. Unstable Angina Emerging Therapies
12. Unstable Angina Market Outlook
13. Country-Wise Unstable Angina Market Analysis (2019–2032)
14. Unstable Angina Market Access and Reimbursement of Therapies
15. Unstable Angina Market Drivers
16. Unstable Angina Market Barriers
17. Unstable Angina Appendix
18. Unstable Angina Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
7 hours ago
- National Post
Dilawri Foundation makes historic $60-million donation to VGH, UBC
Article content Four and a half years ago, Ajay Dilawri's father, Ram Dilawri, began experiencing heart troubles. Article content The Dilawris, founders of Dilawri Automotive Group, the largest automotive dealership in Canada, immediately began consulting with experts at leading heart institutes across the U.S. and around the world, most of whom recommended complex open-heart surgery. Article content Article content Article content 'My father was looking for another, less-frightening option,' said Dilawri. Then they heard about Dr. David Wood, head of the division of cardiology at Vancouver General Hospital and the UBC Hospital. Article content 'We heard that if anyone could save my father's life without open heart surgery, it would be him.' Article content Article content The donation, a gift from the Dilawri Automotive Group's charitable foundation, is the largest in VGH and UBC Hospital history, and will fund the new institute, led by Wood. Article content 'Like so many families, ours has been personally touched by heart disease,' said Dilawri. 'It's a cause that hits close to home.' Article content Wood's vision, of a leading cardiovascular institute in Vancouver, was bold. Article content 'Why can't we create the Mayo Clinic of the North right here in Vancouver?' Wood said at Thursday's event. Article content Article content Article content Article content Wood said the institute will have 15 centres that will be ready to treat patients immediately, and will include centres for Indigenous heart health, women's heart health, youth heart health, and core research areas such as a centre for AI, data science and imaging, as well as the centre for cardiovascular innovation. Article content 'We are going to transform how we care for patients. Replacing heart valves on patients, and going home three hours later — using new technologies to treat heart rhythm problems before they become permanent, so you can go on to live a long and healthy life, minimally invasive heart surgery using robots and small incisions,' said Wood.
CBC
9 hours ago
- CBC
P.E.I. leads Canada in access to gender-affirming care, but more supports still needed
As other parts of Canada dial back access to gender-affirming care, Prince Edward Island and Yukon are leading the country in that metric. Advocates say they are proud of the work being done in this province, but want more support following medical procedures. CBC's Tony Davis reports.
CTV News
10 hours ago
- CTV News
Poor air quality due to wildfire smoke across southwestern Ontario, including Waterloo Region, Guelph and Brant County
The view from the CTV News Kitchener tower on Tuesday, June 6 shows a haze over the skyline in Waterloo region as wildfires burn in northeastern Ontario and Quebec. (CTV) Environment Canada has reported poor air quality early Friday across southwestern Ontario. The agency stated the wildfire smoke will be expected into Friday afternoon and can cause trouble breathing and reduced visibility. Health risks Environment Canada said as the smoke levels increase, people over 65-years-old, pregnant people, youth and infants and people with existing illness and health conditions are more likely to be affected. Some individuals may experience symptoms such as irritation to the eyes, nose and throat, headaches and a mild cough. In some cases, serious symptoms such as wheezing, chest pains and a severe cough are possible. How to reduce impact Environment Canada recommends limiting going outside and to reschedule or reduce outdoor sports and other activities. Anyone working outside should consider wearing a proper-fitting face mask such as a NIOSH-certified N95. The agency said those inside should keep windows and doors closed as much as possible. With these measures in place, Environment Canada said though exposure to pollution is reduced, there may still be symptoms and health risks. Anyone who thinks they are having a medical emergency should immediately seek medical assistance.
